Avacta Share Discussion Threads

[fieldhouse] 17/9/2024 08:59

I would like to see a statement from avacta clarifying data in simple terms that analysts can understand

[pwhite73] 17/9/2024 08:57

fieldhouse - "The efficacy data is not what was being researched. Safety and tolerability were the phased trial."

That's the problem. It has been in this phase trial for the past three years with no sign it is coming out. The company dared to dip its toes into the efficacy domain and was rightly shot down by Deutsche Bank analyst (and yes they do know what they are talking about).

[patio58] 17/9/2024 08:54

The analyst's note is a disgrace and lacks basic knowledge of Avacta's work. Should be withdrawn immediately.

[fieldhouse] 17/9/2024 08:45

DB have not been exactly fans of avacta. 40p has been their base price for a long time.
I have not seen the translation.
Just an analysist’s opinion ! Are they medical oncologists ?
The efficacy data is not what was being researched.Safety and tolerability were the phased trial. Patients had all had two courses of drugs prior to ava6000.
Phase 2 will test the efficacy with various sarcoma fap rich patients that are at various stages of disease progression.
DB analysts will be then able to make proper evaluated statements.Until then everything is to play for.

[sandcrab2] 17/9/2024 08:31

Esting.com - Deutsche Bank (ETR:DBKGn) has lowered the rating for Avacta (LON:AVCT) from "Hold" to "Sell" at the ESMO Congress in Barcelona according to phase 1 data on the active ingredient AVA6000. Analyst Paul Cuddon justified the decision in a study available on Monday by saying that the data presented did not meet expectations.

Of the 57 patients treated with various doses of AVA6000, only three had a partial response (PR), while six patients had a mild reaction. These response rates are neither competitive with established treatment methods nor with new therapeutic approaches, Cuddon wrote.

Avacta divided the patients into two groups based on the expected expression level of the target antigen (Fibroblast Activating Protein, FAP) from scientific publications. In the group with higher expected expression values, three patients showed a partial and four a minor reaction. However, no patient showed a complete response, according to the analyst. In the FAP-middle group, none of the patients showed even a partial response.

The price target left Cuddon unchanged at 40 pence, the last closing price was at 70 pence.

[amanitaangelicus] 16/9/2024 16:23

65p needs to hold or this will see 40's again. Data from an mtd pp t of view is good. Efficacy, sorry but I can't get excited..Better warheads reqd etc. Death spiral stuff, plus long wait now for anything new - and we.re gannin doon.Peeps,small pi.s will want another punt. I.d sell and rebuy at 40p ISH. It happens. Smith failed to line up and farm in ,licensing - anecdotal evidence of efficacy not good enough. Pity

[sandcrab2] 16/9/2024 16:20

1347 is a cornerstone investor

As any fule kno

[cheshire pete] 16/9/2024 14:07

Are you invested in Avacta 1347? Doesn't sound like it to me.

[divmad] 16/9/2024 09:35

So, all good otherwise?

[1347] 16/9/2024 08:14

A bit more positive information in there, I'll look at the details later, but the basic facts remain. Without a Phase 2 trial and more quantative efficacy data it remains in the promising but unproven category and it's taken over 3 years to get this far (or 10 if you count from when Arisaph were doing their 'trials'). Meanwhile the death spiral finance is still running and I have seen no interest from any BPs thus far and their Diagnostics division was a train crash that's still ongoing.

[bonzo] 16/9/2024 08:08

Results as good as you could ever hope for on a Phase 1 study.

[fieldhouse] 16/9/2024 08:01

“Buy on the rumour”, “sell on the news” seems to be happening !
My guess is that Avacta will want to licence ava6000 with limited use for Dox and keep the pipeline clear to licence multiple differing warheads.
What we are seeing is just the tip of an iceberg !

[vertizeasun] 16/9/2024 07:11

I wonder what the patients think about death spiral finance?

[amanitaangelicus] 16/9/2024 06:37

Long way to go. MTB the easy bit! Now it's efficacy,the hard part. Smith knows the game.Avacta gonna have to keep the mkt interested somehow. Get ready for the new AVA streams. It s inbound.Without licensing/ farm in deals this could easily slow to a dribble as impatience, the death spiral convis take their toll.GL though! Enjoying the ride

[fieldhouse] 15/9/2024 10:30

Blackhorse,
I don’t expect one near term.

News about the DX division and licence deals will hopefully give cash runway until phase two trials complete. Then , who knows what cash and interesting deals will be done.

[fieldhouse] 15/9/2024 09:55

The poster data is extremely encouraging. The length of the trial has clearly enhanced the richness of data to enable progression of the delivery pipeline.
All very positive.

[blackhorse23] 15/9/2024 09:07

When next equity raising?

[dudishes] 15/9/2024 07:56

No doubt some need to wake up.

At a loss right now, but...speaches, peaches and teachers about to let rip how they will get over P1 and P2?

exciting

[dudishes] 15/9/2024 07:49

Forget the arguments, bull as AV6 has been for several years.

How does a short @ 74p, large suit you Sir?

[cheshire pete] 15/9/2024 07:28

Not only safe but it works. Still think about 5 years time 1347?

[1347] 14/9/2024 17:15

The FDA guide and other Phase 1 trials I've looked at, compared to 3 years and counting for Avacta's only Phase 1 trial ever is all the evidence I need. However as you are evidently a berk I'll not respond further to your fatuous posts. Carry on buying if you think AVA6000 (or AVA3996, which is also moving at snail's pace) are game changers but I'll base my decisions on actual efficacy data, espcially after the LFT fiasco, so that'll in about 5 years time then. Still maybe they'll have paid off the death spiral finance by then.